| Literature DB >> 28726114 |
Chun Gu1, Fang Wang1, Zhihui Hou2, Bin Lv2, Yang Wang3, Xiangfeng Cong1, Xi Chen4.
Abstract
The objective of this study is to evaluate the clinical feasibility of serum matrix metalloproteinase-9 (MMP-9) for screening plaque composition as assessed by coronary computed tomography angiography (CCTA) in outpatients with chest pain,and the effects of sex on this feasibility. Eight hundred and sixty-two consecutive outpatients with chest pain were divided into three groups according to the results of CCTA: non-plaque (NP, n = 474), calcified plaques (CPs, n = 179), non-calcified and mixed plaques (NCPs and MPs, n = 209). We found that serum MMP-9 levels were significantly higher in patients with NCPs and MPs compared to those with either NP or CPs, especially in women (649.7 ± 279.8 vs. 485.7 ± 231.6 ng/mL or 515.7 ± 274.5 ng/mL, P < 0.001). MMP-9 showed better identification of NCPs and MPs than other related factors and was an independent predictor for NCPs and MPs both in women and men. The receiver operating characteristic analysis indicated a substantial superiority in women with area under the curve of 0.75 (95% CI 0.69-0.82, P < 0.01), compared with men of 0.59 (95% CI 0.53-0.65, z = 3.71, P < 0.01). The diagnostic tests revealed a moderate risk of the presence of NCPs and MPs with MMP-9 ≥531.6 ng/mL in female patients.Entities:
Keywords: Coronary atherosclerosis; Matrix metalloproteinase-9; Non-calcified and mixed plaques; Screening marker; Sex difference
Mesh:
Substances:
Year: 2017 PMID: 28726114 DOI: 10.1007/s00380-017-1014-3
Source DB: PubMed Journal: Heart Vessels ISSN: 0910-8327 Impact factor: 2.037